Rain Oncology Goes Private Just Two Years After $120M NASDAQ Debut
Rain Oncology Inc (NASDAQ: RAIN) has agreed to be acquired by Pathos AI Inc.
Reported Earlier, Rain Oncology To Be Acquired By Pathos AI For $1.16/Share Plus Additional Contingent Value Rights
Pursuant and subject to the terms of the merger agreement, a subsidiary of Pathos will commence a tender offer to acquire all outstanding shares of Rain for $1.16 in cash per share plus a CVR representing a
Rain Oncology And 3 Other Stocks Under $1 Insiders Are Buying
The Dow Jones closed slightly higher on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers Bellerophon Therapeutics (NASDAQ:BLPH) stock moved upwards by 17.1% to $0.12 during Friday’s after-market session. Trading volume for…
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers Bionomics (NASDAQ:BNOX) stock moved upwards by 22.0% to $2.11 during Monday’s after-market session. Bionomics’s trading volume hit…
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell
• IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
10 Short Squeeze Stocks To Watch: Aeglea Biotherapeutics, Toro Corp, AirSculpt, A Company Moves Up 4,166 Positions & More
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move.
High short interest and steep borrowing costs are among the common traits that could lead to a short squeeze.